Your new experience awaits. Try the new design now and help us make it even better

REVIEW article

Oncol. Rev.

Sec. Oncology Reviews: Reviews

Volume 19 - 2025 | doi: 10.3389/or.2025.1613704

Radiation-Induced Intestinal Injury: From Molecular Mechanisms to Clinical Translation

Provisionally accepted
Wenjue  WuWenjue Wu1,2*Zhi  YangZhi Yang1,2Yubo  CaiYubo Cai1,2Mengshuang  ChenMengshuang Chen1,2Jianyang  HuJianyang Hu1,2Kunlong  QuKunlong Qu1,2Jian  YangJian Yang1,2
  • 1Zhejiang Cancer Hospital, Hangzhou, China
  • 2Cancer Research Institute, Zhejiang Cancer Hospital, Hangzhou, Jiangsu Province, China

The final, formatted version of the article will be published soon.

Radiation-induced intestinal injury (RIII) poses a significant clinical challenge for patients undergoing pelvic or abdominal radiotherapy, characterized by dual features of acute symptoms (diarrhea, abdominal pain, rectal bleeding) and chronic complications (stricture, fistula, chronic pain), profoundly impacting quality of life. Despite high clinical prevalence, the molecular and cellular mechanisms underlying RIII remain poorly defined, hindering therapeutic development. Current diagnostic modalities (imaging, endoscopy) lack sensitivity and specificity for early detection or real-time monitoring. While biomarkers offer promise for non-invasive assessment and prognosis, existing candidates face limitations in reproducibility and clinical applicability. Therapeutic options, ranging from pharmaceuticals to surgery, show variable efficacy, underscoring the need for optimized strategies. This review systematically explores RIII pathogenesis, emphasizing radiation-induced immune dysregulation, epigenetic alterations, and gut microbiota dysbiosis. We discuss potential biomarkers, such as miRNA, fatty acid binding proteins (FABPs), etc. We categorize therapies into radioprotectors (pre-radiation use) and radiomitigators (post-radiation intervention), highlighting natural plant-derived compounds and traditional Chinese medicine (TCM) for their multi-target effects, alongside emerging approaches like stem cell and microbiota transplantation, with discussions on their therapeutic potential and clinical challenges. Crucially, we exclusively summarize recent clinical translation advances to accelerate drug development. Through critical evaluation of evidence, we propose future directions to refine risk stratification, enable timely intervention, and improve long-term outcomes for irradiated patients. This integrative analysis aims to bridge translational gaps and prioritize research avenues for RIII management.

Keywords: radiation-induced intestinal injury, Pathogenesis, diagnosis, biomarkers, treatment strategies

Received: 17 Apr 2025; Accepted: 05 Aug 2025.

Copyright: © 2025 Wu, Yang, Cai, Chen, Hu, Qu and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Wenjue Wu, Zhejiang Cancer Hospital, Hangzhou, China

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.